Sprint Bioscience (SPRINT.ST) Stock Price

Sprint Bioscience Price

OMX·CLOSED
3.60SEK-0.13 (-3.55 %)
Market closed

Revenue has compounded at 36.3% per year over the past 12 years to 65.64 M SEK. Sprint Bioscience's net margin stands at -27.8%, up from -253.4% several years earlier. The stock trades about 543% above its 52-week low.

Sprint Bioscience stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sprint Bioscience over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sprint Bioscience stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sprint Bioscience's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sprint Bioscience Stock Price History
DateSprint Bioscience Price
7/31/20263.60 SEK
7/30/20263.73 SEK
7/29/20263.72 SEK
7/28/20263.65 SEK
7/27/20263.72 SEK
7/24/20263.66 SEK
7/23/20263.70 SEK
7/22/20263.58 SEK
7/21/20263.59 SEK
7/20/20263.54 SEK
7/17/20263.67 SEK
7/15/20263.66 SEK
7/14/20263.84 SEK
7/13/20263.83 SEK
7/10/20263.86 SEK
7/9/20263.80 SEK
7/8/20263.76 SEK
7/7/20263.86 SEK
7/6/20263.70 SEK
7/3/20264.04 SEK
7/2/20264.06 SEK
7/1/20264.27 SEK
6/30/20264.14 SEK
6/29/20264.30 SEK
6/26/20264.45 SEK
6/25/20264.49 SEK
6/24/20264.15 SEK
6/23/20264.08 SEK
6/22/20264.30 SEK
6/18/20264.39 SEK
6/17/20264.37 SEK
6/16/20264.32 SEK
6/15/20264.12 SEK
6/12/20263.68 SEK
6/11/20263.71 SEK
6/10/20263.64 SEK
6/9/20263.38 SEK
6/8/20263.27 SEK
6/5/20263.43 SEK
6/4/20263.31 SEK
6/3/20263.50 SEK
6/2/20263.39 SEK
6/1/20263.26 SEK
5/29/20263.47 SEK
5/28/20263.62 SEK
5/27/20263.52 SEK
5/26/20263.51 SEK
5/25/20263.54 SEK
5/22/20263.27 SEK
5/21/20263.59 SEK
5/20/20263.42 SEK
5/19/20263.60 SEK
5/18/20263.43 SEK
5/15/20263.62 SEK
5/13/20263.60 SEK
5/12/20263.66 SEK
5/11/20263.93 SEK
5/8/20263.99 SEK
5/7/20263.67 SEK
5/6/20263.52 SEK
5/5/20263.46 SEK
5/4/20263.22 SEK
4/30/20263.11 SEK
4/29/20263.22 SEK
4/28/20263.14 SEK
4/27/20263.11 SEK
4/24/20262.95 SEK
4/23/20262.89 SEK
4/22/20263.14 SEK
4/21/20263.13 SEK
4/20/20263.28 SEK
4/17/20263.39 SEK
4/16/20263.29 SEK
4/15/20263.87 SEK
4/14/20264.04 SEK
4/13/20263.75 SEK
4/10/20263.66 SEK
4/9/20263.30 SEK
4/8/20262.95 SEK
4/7/20262.61 SEK
4/2/20262.50 SEK
4/1/20262.60 SEK
3/31/20262.38 SEK
3/30/20262.31 SEK
3/27/20262.24 SEK
3/26/20262.09 SEK
3/25/20262.11 SEK
3/24/20261.98 SEK
3/23/20262.04 SEK
3/20/20262.04 SEK
3/19/20262.00 SEK
3/18/20262.11 SEK
3/17/20262.13 SEK
3/16/20262.04 SEK
3/13/20261.93 SEK
3/12/20261.88 SEK
3/11/20261.86 SEK
3/10/20261.91 SEK
3/9/20261.89 SEK
3/6/20261.88 SEK
3/5/20261.89 SEK
3/4/20261.92 SEK
3/3/20261.86 SEK
3/2/20261.88 SEK
2/27/20261.98 SEK
2/26/20262.09 SEK
2/25/20262.15 SEK
2/24/20262.18 SEK
2/23/20262.22 SEK
2/20/20262.21 SEK
2/19/20262.18 SEK
2/18/20262.14 SEK
2/17/20262.02 SEK
2/16/20262.17 SEK
2/13/20262.17 SEK
2/12/20262.21 SEK
2/11/20261.70 SEK
2/10/20261.87 SEK
2/9/20261.85 SEK
2/6/20261.70 SEK
2/5/20261.60 SEK
2/4/20261.66 SEK
2/3/20261.66 SEK
2/2/20261.63 SEK
1/30/20261.63 SEK
1/29/20261.60 SEK
1/28/20261.63 SEK
1/27/20261.64 SEK
1/26/20261.49 SEK
1/23/20261.48 SEK
1/22/20261.48 SEK
1/21/20261.46 SEK
1/20/20261.50 SEK
1/19/20261.50 SEK
1/16/20261.56 SEK
1/15/20261.54 SEK
1/14/20261.51 SEK
1/13/20261.50 SEK
1/12/20261.56 SEK
1/9/20261.56 SEK
1/8/20261.54 SEK
1/7/20261.51 SEK
1/5/20261.50 SEK
1/2/20261.49 SEK
12/30/20251.47 SEK
12/29/20251.48 SEK
12/23/20251.45 SEK
12/22/20251.42 SEK
12/19/20251.43 SEK
12/18/20251.42 SEK
12/17/20251.45 SEK
12/16/20251.42 SEK
12/15/20251.43 SEK
12/12/20251.47 SEK
12/11/20251.46 SEK
12/10/20251.44 SEK
12/9/20251.47 SEK
12/8/20251.48 SEK
12/5/20251.52 SEK
12/4/20251.59 SEK
12/3/20251.63 SEK
12/2/20251.57 SEK
12/1/20251.57 SEK
11/28/20251.58 SEK
11/27/20251.62 SEK
11/26/20251.50 SEK
11/25/20251.50 SEK
11/24/20251.44 SEK
11/21/20250.67 SEK
11/20/20250.64 SEK
11/19/20250.69 SEK
11/18/20250.67 SEK
11/17/20250.70 SEK
11/14/20250.68 SEK
11/13/20250.64 SEK
11/12/20250.65 SEK
11/11/20250.65 SEK
11/10/20250.67 SEK
11/7/20250.71 SEK
11/6/20250.73 SEK
11/5/20250.72 SEK
11/4/20250.70 SEK
11/3/20250.72 SEK
10/31/20250.70 SEK
10/30/20250.69 SEK
10/29/20250.73 SEK
10/28/20250.71 SEK
10/27/20250.71 SEK
10/24/20250.70 SEK
10/23/20250.70 SEK
10/22/20250.70 SEK
10/21/20250.70 SEK
10/20/20250.70 SEK
10/17/20250.73 SEK
10/16/20250.73 SEK
10/15/20250.73 SEK
10/14/20250.75 SEK
10/13/20250.72 SEK
10/10/20250.67 SEK
10/9/20250.64 SEK
10/8/20250.67 SEK
10/7/20250.70 SEK
10/6/20250.70 SEK
10/3/20250.61 SEK
10/2/20250.58 SEK
10/1/20250.59 SEK
9/30/20250.58 SEK
9/29/20250.57 SEK
9/26/20250.56 SEK
9/25/20250.56 SEK
9/24/20250.58 SEK
9/23/20250.59 SEK
9/22/20250.56 SEK
9/19/20250.56 SEK
9/18/20250.57 SEK
9/17/20250.59 SEK
9/16/20250.56 SEK
9/15/20250.59 SEK
9/12/20250.61 SEK
9/11/20250.60 SEK
9/10/20250.60 SEK
9/9/20250.58 SEK
9/8/20250.61 SEK
9/5/20250.61 SEK
9/4/20250.60 SEK
9/3/20250.60 SEK
9/2/20250.60 SEK
9/1/20250.59 SEK
8/29/20250.57 SEK
8/28/20250.56 SEK
8/27/20250.56 SEK
8/26/20250.59 SEK
8/25/20250.60 SEK
8/22/20250.61 SEK
8/21/20250.59 SEK
8/20/20250.59 SEK
8/19/20250.61 SEK
8/18/20250.61 SEK
8/15/20250.60 SEK
8/14/20250.59 SEK
8/13/20250.60 SEK
8/12/20250.60 SEK
8/11/20250.59 SEK
8/8/20250.60 SEK
8/7/20250.57 SEK
8/6/20250.60 SEK
8/5/20250.60 SEK
Access this data via the Eulerpool API
Get Free API Key

Sprint Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
35.11 M SEK
-25.63 M SEK
-25.08 M SEK
Jan 1, 2022
83,000.00 SEK
-60.74 M SEK
-60.17 M SEK
Jan 1, 2023
50.49 M SEK
-845,000.00 SEK
-438,000.00 SEK
Jan 1, 2024
65.64 M SEK
-19.67 M SEK
-18.28 M SEK
Jan 1, 2025 (e)
20.20 M SEK
-5.70 M SEK
7.10 M SEK
Jan 1, 2026 (e)
84.80 M SEK
-23.94 M SEK
21.30 M SEK
Jan 1, 2027 (e)
155.00 M SEK
-43.76 M SEK
35.50 M SEK
Jan 1, 2028 (e)
94.00 M SEK
-26.54 M SEK
0.00 SEK

Sprint Bioscience Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 2:22 AM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
2013201420152016201720182019202020212022202320242025e2026e2027e2028e
2.00–7.0034.0023.0017.0033.0016.0035.00–50.0065.0020.0084.00155.0094.00
100.00––385.71-32.35-26.0994.12-51.52118.75––30.00-69.23320.0084.52-39.35
250.00–100.00100.0086.9641.1875.7637.5068.57–82.0056.9256.9256.9256.9256.92
5.001.007.0034.0020.007.0025.006.0024.00-12.0041.0037.0011.3847.8288.2353.51
-4.00-11.00-15.004.00-10.00-31.00-20.00-37.00-25.00-60.00–-19.00-5.00-23.00-43.00-26.00
-200.00–-214.2911.76-43.48-182.35-60.61-231.25-71.43––-29.23-25.00-27.38-27.74-27.66
-4.00-11.00-15.004.00-10.00-31.00-21.00-42.00-25.00-60.00–-18.007.0021.0035.00–
33.33175.0036.36-126.67-350.00210.00-32.26100.00-40.48140.00––-138.89200.0066.67–
6.546.547.119.4710.1511.8515.0420.7034.6542.7770.9971.0071.0071.0071.0071.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sprint Bioscience generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sprint Bioscience retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sprint Bioscience's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sprint Bioscience has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sprint Bioscience's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sprint Bioscience stock margins

The Sprint Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sprint Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sprint Bioscience.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
38.06 %
-223.13 %
-253.43 %
Jan 1, 2021
70.28 %
-72.99 %
-71.43 %
Jan 1, 2022
-15,478.31 %
-73,180.72 %
-72,493.98 %
Jan 1, 2023
82.77 %
-1.67 %
-0.87 %
Jan 1, 2024
56.83 %
-29.96 %
-27.84 %
Jan 1, 2025 (e)
56.83 %
-28.23 %
35.15 %
Jan 1, 2026 (e)
56.83 %
-28.23 %
25.12 %
Jan 1, 2027 (e)
56.83 %
-28.23 %
22.90 %

Sprint Bioscience Stock Revenue, EBIT, Earnings per Share

The Sprint Bioscience earnings per share therefore indicates how much revenue Sprint Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.82 SEK
-1.82 SEK
-2.07 SEK
Jan 1, 2021
1.01 SEK
-0.74 SEK
-0.72 SEK
Jan 1, 2022
0.00 SEK
-1.42 SEK
-1.41 SEK
Jan 1, 2023
0.71 SEK
-0.01 SEK
-0.01 SEK
Jan 1, 2024
0.92 SEK
-0.28 SEK
-0.26 SEK
Jan 1, 2025 (e)
0.28 SEK
-0.08 SEK
0.10 SEK
Jan 1, 2026 (e)
1.19 SEK
-0.34 SEK
0.30 SEK
Jan 1, 2027 (e)
2.18 SEK
-0.62 SEK
0.50 SEK

Sprint Bioscience business model & stock analysis

The Swedish company Sprint Bioscience AB is an innovative developer of drugs targeted for use in cancer. The company was founded in Stockholm in 2009 and has since worked with a strong focus on molecular research. Sprint Bioscience is a biotechnology company with the goal of developing drugs for various types of cancer. The company's focus is on so-called "trickster molecules" that can prevent tumor cells from taking up nutrients, ultimately leading to their death. The innovative business model of Sprint Bioscience is that they focus on the discovery and development of molecules, which they then sell to larger pharmaceutical companies that further develop and bring them to market. Sprint Bioscience has a wide range of molecular tools that allow for the identification, development, and optimization of cancer therapy drugs. The company aims to accelerate the discovery of new drugs in the field of oncology. Sprint Bioscience is divided into two business areas: discovery, which specializes in the identification and optimization of drugs for use in cancer, and development, which focuses on the preclinical development of drugs that are later further developed by larger pharmaceutical companies. The most well-known product of Sprint Bioscience is the molecule "SB-11285", a novel cancer therapeutic specifically developed for ovarian cancer. The molecule is intended to help destroy cancer cells by disrupting their cellular metabolism and depriving them of their energy source. Sprint Bioscience has also formed partnerships with other companies to exchange technologies and expertise. For example, there is a collaboration with Bayer to develop new oncology drugs. Overall, Sprint Bioscience has undergone significant development in recent years. The company has built strong expertise in the field of molecular research and effectively implemented its business model. Sprint Bioscience presents itself as a promising player in the biotechnology industry and has the potential to achieve further significant progress in the coming years.

Sprint Bioscience SWOT Analysis

Strengths

Sprint Bioscience AB has several strengths that contribute to its success in the market. Firstly, the company possesses a highly skilled and experienced research and development team. This allows them to develop innovative and high-quality products in the field of bioscience. Additionally, Sprint Bioscience has established strategic partnerships with leading pharmaceutical companies, enabling them to access resources and expertise that support their research and development efforts. Another strength is the company's strong financial position, providing them with the necessary resources to fund their projects and operations.

Weaknesses

Despite its strengths, Sprint Bioscience AB also faces certain weaknesses that need to be addressed. One weakness is the company's reliance on a limited product portfolio. This puts them at risk in the event of product failures or market shifts. Furthermore, their relatively small size compared to some competitors may limit their ability to compete on a global scale. Additionally, the company's dependence on external collaborations and partnerships may impact their autonomy and control over their own projects.

Opportunities

Sprint Bioscience AB operates in an industry full of opportunities that they can leverage. Firstly, the growing demand for innovative bioscience products, driven by advancements in healthcare and biotechnology, presents an opportunity for the company to expand its product offerings and increase its market share. Additionally, the increasing focus on personalized medicine and targeted therapies opens up new avenues for Sprint Bioscience to develop specialized products catering to specific patient populations. The company can also explore collaborations with academic institutions or other biotech companies to further enhance their research capabilities.

Threats

While there are opportunities, Sprint Bioscience AB also faces certain threats that could impact their business. One major threat is the intense competition within the bioscience industry. The presence of large, established pharmaceutical companies with significant resources poses a challenge for Sprint Bioscience to maintain market share and differentiate themselves. Moreover, regulatory challenges and the need to comply with strict industry standards can create barriers to entry and hinder product development. External factors such as economic instability or changes in government policies related to healthcare and biotechnology can also impact the company's operations.

Sprint Bioscience Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sprint Bioscience historical P/E ratio, EBIT multiple, and P/S ratio

Sprint Bioscience annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sprint Bioscience shares outstanding

The number of shares of Sprint Bioscience was 71 M in 2025. This indicates how many shares Sprint Bioscience is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
20.70 M Stocks
Jan 1, 2021
34.65 M Stocks
Jan 1, 2022
42.77 M Stocks
Jan 1, 2023
70.99 M Stocks
Jan 1, 2024
71.00 M Stocks
Jan 1, 2025 (e)
71.00 M Stocks
Jan 1, 2026 (e)
71.00 M Stocks
Jan 1, 2027 (e)
71.00 M Stocks
Price targets and forecasts for Sprint Bioscience are not yet available.

Sprint Bioscience Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/17/2021-0.35SEK-2.54 MSEK-2020 Q4
10/28/2020-SEK-2.33 MSEK-2020 Q3
8/26/2020-SEK-4.06 MSEK-2020 Q2

Sprint Bioscience shareholder structure

% Name
23.01508%
First Venture Sweden AB
First Venture Sweden AB
18.04956%
Nordnet Pensionsforsakring AB
Nordnet Pensionsforsakring AB
11.44965%
Nordqvist (Ivar)
Nordqvist (Ivar)
10.97393%
Avanza Bank Holding AB
Avanza Bank Holding AB
8.34540%
Westinius (Mats)
Westinius (Mats)
7.44153%
Poulsen (Jan)
Poulsen (Jan)

Sprint Bioscience Beneficial Ownership Filings (SEC 13D/G)

Free Float
5.7%
Float Shares
-
Shares Outstanding
-

Sprint Bioscience Executives and Management Board

10 members · avg. age 55 · 10 % women

Management

JE

Mr. Johan Emilsson (40)

Chief Executive Officer

–
NA

Mr. Niklas Axelsson

Chief Financial Officer

–
MS

Mr. Mathias Skalmstad (51)

Chief Financial Officer

–
MA

Dr. Martin Andersson (57)

Head of Research

–
AW

Ms. Anne-Marie Wenthzel (59)

Business Development Manager

–

Board of Directors

BS

Mr. Bjoern Sjoestrand (55)

Independent Chairman of the Board

279,000.00 SEK
NN

Mr. Nils Nordlander (67)

Director

140,000.00 SEK
FL

Dr. Fredrik Lehmann (48)

Independent Director

140,000.00 SEK
SM

Mr. Svein Mathisen (67)

Independent Director

140,000.00 SEK
KF

Mr. Karen From (54)

Director

–

Frequently asked questions about Sprint Bioscience

The business model of Sprint Bioscience AB focuses on developing novel cancer therapies through its drug discovery platform. By combining medicinal chemistry and tumor biology expertise, the company aims to identify and develop drug candidates that target specific cancer-related proteins. Sprint Bioscience AB collaborates with pharmaceutical companies to enhance their drug pipelines and potentially bring new treatment options to patients. With a dedication to precision medicine and innovation, Sprint Bioscience AB strives to address unmet medical needs in the field of oncology.

Sprint Bioscience AB is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Sprint Bioscience AB in the market are other pharmaceutical companies that specialize in drug discovery and development. Some notable competitors include AstraZeneca, Pfizer, Novartis, and Merck. These companies also focus on innovative medical solutions and have a strong presence in the biopharmaceutical industry. While Sprint Bioscience AB has its own unique portfolio of drug candidates, it operates in a competitive landscape where these established players constantly strive to bring new and improved therapies to the market.

Sprint Bioscience AB is a leading biotechnology company specializing in drug discovery and development. Founded in 2009, the company is headquartered in Stockholm, Sweden. Sprint Bioscience AB focuses on developing innovative treatments for cancer by targeting cancer metabolism. With a dedicated team of scientists and researchers, the company utilizes its cutting-edge drug discovery platform to identify and develop potential drug candidates. By collaborating with renowned academic institutions and industry partners, Sprint Bioscience AB aims to advance its drug pipeline and make a positive impact on patients' lives. With a strong commitment to scientific excellence and a focus on delivering breakthrough therapies, Sprint Bioscience AB continues to drive innovation in the field of oncology.

Sprint Bioscience AB, a distinguished biotechnology company, has achieved significant milestones throughout its journey. Notably, the company successfully entered into a collaboration with Bayer AG in 2017, demonstrating its recognition as a valuable partner in drug discovery. Furthermore, in 2019, Sprint Bioscience received a prestigious grant from the European Innovation Council's SME Instrument Phase 2 program to support the development of its cancer drug candidate, SB254, highlighting its innovative research and potential for clinical success. With remarkable collaborations and recognition, Sprint Bioscience AB continues to make remarkable strides in the biotechnology sector.

Sprint Bioscience AB is primarily present in Sweden.

Sprint Bioscience AB represents a set of values and corporate philosophy that drives its operations. With a commitment to innovation and scientific excellence, Sprint Bioscience focuses on discovering and developing novel small molecule drugs for targeted cancer therapies. The company values integrity, collaboration, and transparency in its approach to research and development. By leveraging its expertise in fragment-based drug discovery, Sprint Bioscience aims to deliver transformative treatments that address unmet medical needs. Through its dedication to cutting-edge science and a patient-centric approach, Sprint Bioscience strives to make a positive impact in the field of oncology.

Converted at the current exchange rate, the Sprint Bioscience share trades at 0.33 EUR (3.60 SEK).

The Sprint Bioscience share (SPRINT.ST) is listed on 4 stock exchanges, including: Frankfurt (5JA1.F), München (5JA1.MU).

Sprint Bioscience AB is a biopharmaceutical company based in Stockholm, Sweden. Founded in 2009, the company focuses on the discovery and development of drugs for cancer and autoimmune diseases. Sprint Bioscience's business model is based on identifying targeted molecules that play a crucial role in the onset and spread of diseases. These molecules are considered potential drug candidates and are tested in preclinical and clinical trials. The company operates three business divisions that focus on different aspects of drug development: discovery, development, and partnering. Sprint Bioscience's discovery division is responsible for identifying potential drugs. The company has a proprietary technology platform that allows for the systematic and efficient identification and optimization of chemicals. The development division handles the preclinical and clinical testing phases of drug development. The company has its own laboratory facilities for chemical synthesis and analysis of drugs. The partnering division focuses on collaborating with other companies to jointly develop drugs. The company has experience in licensing drug candidates to pharmaceutical companies and also engages in partnership collaborations. Currently, Sprint Bioscience does not offer any products on the market. The company is still in the development phase, and major milestones are expected to be achieved in the coming years. However, Sprint Bioscience has a promising pipeline of drug candidates for various types of cancer and autoimmune diseases. The main drug candidate of Sprint Bioscience is the SB-19 active substance candidate, which has a potential medical application for the treatment of stomach and colorectal cancer. The company recently entered into a collaboration agreement with the American biotech company BioInvent to accelerate the clinical development of SB-19. In 2019, Sprint Bioscience also signed a collaboration agreement with the major Japanese pharmaceutical company Daiichi Sankyo. The collaboration focuses on the discovery of new drug candidates targeting a specific molecule associated with cancer. In summary, Sprint Bioscience's business model is based on the identification and development of new drug candidates for cancer and autoimmune diseases. The company operates three business divisions focusing on different aspects of drug development and has promising drug candidates in its pipeline.

The expected revenue of Sprint Bioscience is 84.80 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sprint Bioscience is 21.30 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sprint Bioscience is currently 12.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sprint Bioscience stock.

The price-to-sales ratio (P/S) of Sprint Bioscience is currently 3.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sprint Bioscience stock.

The Eulerpool Quality Score for Sprint Bioscience is 3/10.

The ISIN of Sprint Bioscience is SE0006343745. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sprint Bioscience is A14NY2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sprint Bioscience is SPRINT.ST. The ticker symbol is used to trade Sprint Bioscience shares on the stock exchange.

Sprint Bioscience paid dividends every year for the past 0 years.

Sprint Bioscience is assigned to the 'Health' sector.

The dividends of Sprint Bioscience are distributed in SEK.

All fundamentals and in-depth analysis of Sprint Bioscience

Our stock analysis for Sprint Bioscience stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sprint Bioscience. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sprint Bioscience Stock
Sprint Bioscience Revenue→
Sprint Bioscience Stock
Sprint Bioscience Net Income→
Sprint Bioscience Stock
Sprint Bioscience P/E→
Sprint Bioscience Stock
Sprint Bioscience P/S→
Sprint Bioscience Stock
Sprint Bioscience EBIT→
Sprint Bioscience Stock
Sprint Bioscience Dividend→
Sprint Bioscience Stock
Sprint Bioscience Directors Dealings→
Sprint Bioscience Stock
Sprint Bioscience Stocks→
Sprint Bioscience Stock
Sprint Bioscience Market capitalization→
Sprint Bioscience Stock
Sprint Bioscience Debt→
Sprint Bioscience Stock
Sprint Bioscience Liabilities→
Sprint Bioscience Stock
Sprint Bioscience Equity→
Sprint Bioscience Stock
Sprint Bioscience AAQS→
Sprint Bioscience Stock
Sprint Bioscience Employees→
Sprint Bioscience Stock
Sprint Bioscience ROE→
Sprint Bioscience Stock
Sprint Bioscience ROA→
Sprint Bioscience Stock
Sprint Bioscience ROCE→
Sprint Bioscience Stock
Sprint Bioscience News→
Sprint Bioscience Stock
Sprint Bioscience Analyst Price Targets→

Health Stocks

Spruce BiosciencesSPO GlobalSpyre TherapeuticsSPMSQZ BiotechnologiesSpirit Scientific CoSri Trang Gloves (Thailand) PCLSpire Healthcare GroupSrivichai vejvivat PCLSpinewaySS Innovations InternationalSpineguardAll Stocks A–Z →